NCT03618667

GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification

A Phase II Clinical Study of GC1118 in Recurrent Glioblastoma Patients With High Epidermal Growth Factor Receptor (EGFR) Amplification

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: Samsung Medical Center · Academic / Other
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

This study is a phase 2 trial of GC1118, an EGFR monoclonal antibody, for recurrent glioblastoma patients who were treated with standard concurrent chemoradiation.

Detailed description

This study is a phase 2 trial of GC1118, an EGFR monoclonal antibody, for recurrent glioblastoma patients who were treated with standard concurrent chemoradiation. GC1118 (4mg/kg) will be administered by IV infusion once per week for 4 weeks(28-day cycle) up to 6 cycles.

Conditions

• Glioblastoma, Adult
• EGFR Amplification

Interventions

Type	Name	Description
DRUG	GC1118	GC1118 (4mg/kg) will be administered by IV infusion once per week for 4 weeks(28-day cycles) up to 6 cycles, or till progression or uncontrolled toxicity.

Timeline

• Start date: 2018-01-22
• Primary completion: 2018-09-08
• Completion: 2022-04-28
• First posted: 2018-08-07
• Last updated: 2023-05-12

Locations

1 site across 1 country: South Korea